ReviewCardiology research2017
Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.
Review in Cardiology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Integrated meta-analysis and network pharmacology analysis: evaluation of Zhigancao decoction as treatment for diabetic cardiomyopathy.Frontiers in cardiovascular medicine · 2025Pooled it
- Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022Pooled it
- Arginine vasopressin induces ferroptosis to promote heart failure via activation of the V1aR/CaN/NFATC3 pathway.Acta biochimica et biophysica Sinica · 2024Article
- Identification of Shared Signature Genes and Immune Microenvironment Subtypes for Heart Failure and Chronic Kidney Disease Based on Machine Learning.Journal of inflammation research · 2024Article
- Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.European journal of histochemistry : EJH · 2022Article
- Serum Osmolarity and Vasopressin Concentration in Acute Heart Failure-Influence on Clinical Course and Outcome.Biomedicines · 2022Article
- Predictive Value of Urinary Aquaporin 2 for Acute Kidney Injury in Patients with Acute Decompensated Heart Failure.Biomedicines · 2022Article
- Apela inhibits systemic and renal inflammatory reactions in mice with type I cardiorenal syndrome.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management.Cureus · 2021Review
- Deciphering key genes in cardio-renal syndrome using network analysis.Bioinformation · 2021Article
- An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome.Cardiology research · 2020Review
- Over-expression of arginine vasopressin in magnocellular neurosecretory cells of hypothalamus and its potential relationship with development of diabetic nephropathy.Archives of medical science : AMS · 2020Article
- Correlation between miRNA target site polymorphisms in the 3' UTR ofBioscience reports · 2019Article
- Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.Internal medicine (Tokyo, Japan) · 2019Review
- Hyponatremia in Heart Failure: Pathogenesis and Management.Current cardiology reviews · 2019Review
- New therapies for the treatment of heart failure: a summary of recent accomplishments.Therapeutics and clinical risk management · 2019Review
- Article
- Efficacy of oral tolvaptan versus 3% hypertonic saline for correction of hyponatraemia in post-operative patients.Indian journal of anaesthesia · 2017Article
- HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan.Pakistan journal of medical sciencesArticle
- Hyponatremia: A role for vasopressin receptor antagonists?Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart and kidney failure continued to be of increasing prevalence in today's society, and their comorbidity has synergistic effect on the morbidity and mortality of patients. Cardiorenal syndrome (CRS) is a complex disease with multifactorial pathophysiology. Better understanding of this pathophysiological network is crucial for the successful intervention to prevent advancement of the disease process. One of the major factors in this process is neurohormonal activation, predominantly involving renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP). Heart failure causes reduced cardiac output/cardiac index (CO/CI) and fall in renal perfusion pressures resulting in activation of baroreceptors and RAAS, respectively. Activated baroreceptors and RAAS stimulate the release of AVP (non-osmotic pathway), which acts on V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.